Latest Insider Transactions at Edgewise Therapeutics, Inc. (EWTX)
This section provides a real-time view of insider transactions for Edgewise Therapeutics, Inc. (EWTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Edgewise Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Edgewise Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 12
2025
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
100,000
-81.04%
|
$2,100,000
$21.12 P/Share
|
|
Nov 12
2025
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+44.76%
|
$0
$0.18 P/Share
|
|
Nov 11
2025
|
Jonathan C Fox |
BUY
Open market or private purchase
|
Direct |
10,700
+31.1%
|
$192,600
$18.64 P/Share
|
|
Oct 01
2025
|
Jonathan C Fox |
BUY
Grant, award, or other acquisition
|
Direct |
728
+5.3%
|
-
|
|
Aug 26
2025
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
100,000
-81.04%
|
$1,400,000
$14.6 P/Share
|
|
Aug 26
2025
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+44.76%
|
$0
$0.18 P/Share
|
|
Aug 12
2025
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
2,862
-10.14%
|
$37,206
$13.39 P/Share
|
|
Aug 12
2025
|
Joanne M. Donovan CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,781
+17.0%
|
-
|
|
Aug 12
2025
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
7,972
-20.66%
|
$103,636
$13.39 P/Share
|
|
Aug 12
2025
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,968
+31.77%
|
-
|
|
Aug 12
2025
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,907
-7.54%
|
$24,791
$13.39 P/Share
|
|
Aug 12
2025
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,781
+18.6%
|
-
|
|
Aug 12
2025
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,428
-1.63%
|
$18,564
$13.39 P/Share
|
|
Aug 12
2025
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,781
+6.19%
|
-
|
|
Aug 12
2025
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,491
-9.53%
|
$32,383
$13.39 P/Share
|
|
Aug 12
2025
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,781
+18.11%
|
-
|
|
Aug 12
2025
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
2,098
-17.04%
|
$27,274
$13.39 P/Share
|
|
Aug 12
2025
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,781
+31.95%
|
-
|
|
Jul 01
2025
|
Jonathan C Fox |
BUY
Grant, award, or other acquisition
|
Direct |
858
+6.53%
|
-
|
|
May 02
2025
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
5,187
-19.37%
|
$82,992
$16.45 P/Share
|
|
May 02
2025
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
4,276
-17.18%
|
$68,416
$16.45 P/Share
|
|
May 02
2025
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
1,930
-22.81%
|
$30,880
$16.45 P/Share
|
|
May 02
2025
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,551
-7.73%
|
$24,816
$16.45 P/Share
|
|
May 02
2025
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,314
-1.6%
|
$21,024
$16.45 P/Share
|
|
May 02
2025
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,691
-7.67%
|
$27,056
$16.45 P/Share
|
|
May 01
2025
|
Joanne M. Donovan CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+28.01%
|
-
|
|
May 01
2025
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+29.5%
|
-
|
|
May 01
2025
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,209
+38.11%
|
-
|
|
May 01
2025
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,209
+20.6%
|
-
|
|
May 01
2025
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,209
+5.95%
|
-
|
|
May 01
2025
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,209
+19.11%
|
-
|
|
Apr 03
2025
|
Peter A. Thompson |
BUY
Open market or private purchase
|
Indirect |
496,771
+12.16%
|
$9,935,420
$20.13 P/Share
|
|
Apr 03
2025
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
496,771
+12.16%
|
$9,935,420
$20.13 P/Share
|
|
Apr 01
2025
|
Jonathan C Fox |
BUY
Grant, award, or other acquisition
|
Direct |
559
+4.67%
|
-
|
|
Mar 07
2025
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
100
-0.69%
|
$3,000
$30.0 P/Share
|
|
Mar 07
2025
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.68%
|
$0
$0.18 P/Share
|
|
Mar 07
2025
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
200
-1.33%
|
$6,000
$30.02 P/Share
|
|
Mar 07
2025
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.31%
|
$0
$0.18 P/Share
|
|
Feb 06
2025
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
900
-5.85%
|
$27,900
$31.13 P/Share
|
|
Feb 06
2025
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+5.53%
|
$11,700
$13.11 P/Share
|
|
Feb 06
2025
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,200
-7.47%
|
$36,000
$30.13 P/Share
|
|
Feb 06
2025
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+6.95%
|
$0
$0.18 P/Share
|
|
Feb 05
2025
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
10,000
-37.26%
|
$300,000
$30.03 P/Share
|
|
Feb 05
2025
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+27.15%
|
$10,000
$1.93 P/Share
|
|
Feb 05
2025
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
8,636
-37.36%
|
$259,080
$30.03 P/Share
|
|
Feb 05
2025
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+27.2%
|
$0
$0.18 P/Share
|
|
Feb 05
2025
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,015
-35.03%
|
$240,450
$30.02 P/Share
|
|
Feb 05
2025
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,015
+25.94%
|
$0
$0.18 P/Share
|
|
Jan 28
2025
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
25,000
-60.45%
|
$675,000
$27.63 P/Share
|
|
Jan 28
2025
|
Joanne M. Donovan CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+37.67%
|
$175,000
$7.08 P/Share
|